Key terms
About NARI
Inari Medical, Inc. operates as a medical device company. The firm develops, manufactures, markets and sells devices for the interventional treatment of venous diseases. Its products include FlowTriever system and ClotTriever system. The company was founded by Brian J. Cox, Paul Lubock and Robert F. Rosenbluth in June 2011 and is headquartered in Irvine, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest NARI news
Apr 03
5:03am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Inari Medical (NARI) and Roivant Sciences (ROIV)
Apr 01
4:55am ET
Inari Medical to replace Callon Petroleum in S&P 600 at open on 4/1
Apr 01
4:55am ET
AppFolio to replace Inari Medical in S&P 400 at open on 4/1
Mar 25
5:26pm ET
Inari Medical to replace Callon Petroleum in S&P 600 at open on 4/1
Mar 25
5:25pm ET
AppFolio to replace Inari Medical in S&P 400 at open on 4/1
Mar 22
9:28am ET
Inari Medical price target lowered to $52 from $61 at Truist
Mar 06
5:35am ET
Inari Medical Buy Rating Justified by Industry-Standard Physician Payments and Resilient Sector Trends
Mar 02
7:10pm ET
SHAREHOLDER ALERT: Potential Recovery for Inari Medical, Inc. (NARI) Investors
Mar 02
7:10pm ET
SHAREHOLDER ALERT: Potential Recovery for Inari Medical, Inc. (NARI) Investors
Mar 02
7:10pm ET
SHAREHOLDER ALERT: Potential Recovery for Inari Medical, Inc. (NARI) Investors
Feb 29
7:41am ET
Inari Medical price target lowered to $75 from $79 at Canaccord
Feb 29
7:32am ET
Inari Medical price target lowered to $86 from $93 at BTIG
Feb 29
7:29am ET
Piper Sandler downgrades Inari Medical to Neutral on core concerns, DOJ probe
Feb 29
7:21am ET
Inari Medical (NARI) Gets a Hold from Truist Financial
Feb 29
6:45am ET
Inari Medical: Strong Buy Rating Amidst Long-Term Growth Prospects and Strategic Initiatives
Feb 29
6:37am ET
Inari Medical’s Strong Financial Outlook and Market Position Affirm Buy Rating Despite DoJ Inquiry
Feb 29
6:05am ET
Inari Medical: A Solid Buy Despite EPS Miss and DOJ Investigation
Feb 29
5:35am ET
Inari Medical downgraded to Neutral from Overweight at Piper Sandler
Feb 28
7:46pm ET
Inari Medical sees FY24 revenue $580M-$595M, consensus $588.3M
Feb 28
4:43pm ET
Inari Medical reports Q4 EPS (8c), consensus 1c
Jan 30
9:25pm ET
Inari Medical (NARI) Receives a Hold from Truist Financial
Jan 23
7:22am ET
Inari Medical initiated with a Buy at Needham
Jan 23
6:55am ET
Inari Medical: A Strong Buy on Untapped Market Potential and Strategic Growth Initiatives
Jan 22
12:50pm ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Definitive Healthcare Corp (DH), Anavex Life Sciences (AVXL) and Inari Medical (NARI)
Jan 10
5:40am ET
Inari Medical: Strong Q4 Performance and Promising Growth Trajectory Justify Buy Rating
Jan 09
6:33am ET
Inari Medical sees FY24 revenue $580M-$595M, consensus $583.07M
Jan 09
6:33am ET
Inari Medical sees 2023 revenue at least $493.5M, consensus $491.37M
Jan 09
6:32am ET
Inari Medical sees Q4 revenue at least $132M, consensus $130.98M
Jan 07
5:38am ET
BTIG Remains a Buy on Inari Medical (NARI)
Jan 05
7:55am ET
Piper Sandler Keeps Their Buy Rating on Inari Medical (NARI)
NARI Financials
Key terms
Ad Feedback
NARI Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
NARI Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
